Recombinant Antibodies

Cetrelimab (anti-PDCD1) is a humanized mAb targeting PD-1. Cetrelimab (anti-PDCD1) binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab (anti-PDCD1)

Cetrelimab (anti-PDCD1) is a humanized mAb targeting PD-1. Cetrelimab (anti-PDCD1) binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab (anti-PDCD1)

Cetrelimab (anti-PDCD1) is a humanized mAb targeting PD-1. Cetrelimab (anti-PDCD1) binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab (anti-PDCD1)

Cixutumumab (anti-IGF1R) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab (anti-IGF1R) also mediates the internalization and degradation of

Cixutumumab (anti-IGF1R) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab (anti-IGF1R) also mediates the internalization and degradation of

Cixutumumab (anti-IGF1R) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab (anti-IGF1R) also mediates the internalization and degradation of

Cixutumumab (anti-IGF1R) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab (anti-IGF1R) also mediates the internalization and degradation of

Conatumumab (anti-TNFRSF10B) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab (anti-TNFRSF10B) induces apoptosis via caspase

Conatumumab (anti-TNFRSF10B) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab (anti-TNFRSF10B) induces apoptosis via caspase

Conatumumab (anti-TNFRSF10B) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab (anti-TNFRSF10B) induces apoptosis via caspase

Conatumumab (anti-TNFRSF10B) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab (anti-TNFRSF10B) induces apoptosis via caspase

Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.